Advertisement
U.S. markets open in 1 hour 54 minutes

Veradigm Inc. (MDRX)

Other OTC - Other OTC Delayed Price. Currency in USD
8.35-0.05 (-0.60%)
At close: 03:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close8.40
Open7.90
Bid0.00 x 2900
Ask0.00 x 1000
Day's Range7.76 - 9.24
52 Week Range5.01 - 14.09
Volume873,094
Avg. Volume4,893,541
Market Cap912.321M
Beta (5Y Monthly)0.62
PE Ratio (TTM)9.71
EPS (TTM)0.86
Earnings DateDec 22, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateOct 07, 2008
1y Target Est14.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
18% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for MDRX

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Veradigm Inc.
    Analyst Report: Veradigm IncVeradigm, formerly Allscripts Healthcare Solutions, is a provider of electronic health record solutions for physicians, group practices, ambulatory facilities, and hospitals. The company also provides practice management systems, clinical software, and connectivity solutions for physicians. The company has approximately 8,000 employees. The shares are a component of the S&P 600 Small-Cap Index.
    Rating
    Fair Value
    Economic Moat
    2 months agoArgus Research
View more
  • Business Wire

    Veradigm to Participate in KeyBanc Capital Markets Life Sciences & MedTech Investor Forum

    CHICAGO, March 14, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm Interim Chief Executive Officer and board member, Lee Westerfield, Interim Chief Financial Officer, and Will Manidis Co-Founder of ScienceIO will participate in a fireside chat at the KeyBanc Capital Markets Life Science & MedTech Investor Forum on Tuesday, March 19th, 2024 at 12:00 PM EDT.

  • Business Wire

    Veradigm Announces Initial Financial Guidance for Fiscal 2024

    CHICAGO, March 13, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today it has reaffirmed the estimated, unaudited ranges for fiscal 2023 of GAAP Revenue, Adjusted EBITDA, and Non-GAAP diluted earnings per share that it provided on January 10, 2024, in the Company’s Form 8-K filed on January 10, 2024, and initially reaffirmed on February 27, 2024.

  • Business Wire

    Veradigm to Participate in Barclays 26th Annual Global Healthcare Conference

    CHICAGO, March 04, 2024--Veradigm Inc. (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions announced today that Dr. Yin Ho, Veradigm interim Chief Executive Officer and board member, Lee Westerfield, interim Chief Financial Officer, and Will Manidis, Senior Vice President and the former CEO of ScienceIO, will participate in a fireside chat and investor Q&A, as well as meet with investor attendees during the Barclays 26th Annual Global Healthcare Conference on Wednesda